Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Completed · Phase 4 · Has a placebo group

Conditions studied: Coronary Artery Disease

In brief

The purpose of this study is to compare sitagliptin and placebo for the prevention of high blood glucose during surgery.

Key facts

Study ID

NCT02443402

Run by

Emory University

People needed

68

Starts

2016-01-01

Expected to finish

2016-12-01

Last updated by the study team

2018-02-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females between the ages of 18 and 80 years undergoing, cardiac surgery
• No previous history of diabetes
• No previous history of hyperglycemia

You may not qualify if…

• Patients with hyperglycemia (blood glucose > 125 mg/dL); or glycated hemoglobin (HbA1c) > 6.5%; or previous treatment with oral antidiabetic agents or insulin
• Severely impaired renal function (serum creatinine ≥3.0 mg/dL or GFR < 30 mL/min) or clinically significant hepatic failure
• Moribund patients and those at imminent risk of death (brain death or cardiac standstill)
• Subjects with gastrointestinal (GI) obstruction or adynamic ileus or those expected to require GI suction
• Patients with clinically relevant pancreatic or gallbladder disease
• Treatment with oral or injectable corticosteroid
• Mental condition rendering the subject unable to understand the scope, and consequences of the study
• Female subjects who are pregnant or breast feeding at time of enrollment into the study

Where it is running

• Grady Health System — Atlanta, Georgia, United States
• Emory University Hospital - Midtown — Atlanta, Georgia, United States
• Emory University Hospital — Atlanta, Georgia, United States
• Emory Saint Joseph's Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.